Skip to main content icon/video/no-internet

The use of pharmacologic agents to treat psychiatric illness has increased dramatically since the advent in the 1950s of chlorpromazine, an antipsychotic drug widely regarded as the first psychotropic medication. Interest in the medication-based treatment of trauma-related disorders such as acute stress disorder (ASD) and posttraumatic stress disorder (PTSD) has grown as those disorders have been more formally characterized and increasingly recognized. A variety of psychotropic agents have been studied both to prevent and treat trauma-related disorders. Certain medications, especially selective serotonin reuptake inhibitors (SSRIs), have shown efficacy in the treatment of noncombat PTSD. Unfortunately, useful preventive pharmacologic interventions and effective treatment for combat-related PTSD remain more elusive. Pharmacologic agents are a mainstay in the treatment of other psychiatric conditions that are also common in the posttrauma period, including depression and substance use disorders. The combined use of medication and psychotherapy has not been adequately studied. However, present evidence and clinical consensus suggest that despite advances in pharma-cotherapy, psychotherapeutic interventions remain an important component of posttraumatic intervention.

Prevention

It has been hypothesized that pharmacologic intervention in the immediate aftermath of a traumatic event may avert the development of both short-term ASD and longer-term PTSD. However, there is little solid evidence that peritraumatic medication is helpful in preventing these disorders. In small studies, beta-adrenergic blockers administered in the wake of a trauma have reduced some symptoms but have not been proven to prevent PTSD. In the event of physical injury, adequate pain control in the acute settings may reduce the likelihood or severity of later PTSD. Benzodiazepines may also improve short-term anxiety and insomnia but have not been demonstrated to be efficacious in treating PTSD. Some evidence suggests that short-term use of benzodiaz-epines around the time of the traumatic event may increase later rates of PTSD. Current guidelines do not recommend any pharmacologic intervention to prevent ASD or PTSD.

Treatment of Acute Stress Disorder

By definition, ASD is a time-limited disorder (if symptoms persist beyond 1 month, PTSD is diagnosed), and treatment for shorter-lived ASD has been less researched than has that for PTSD. The research that has been conducted supports similar treatment as for patients with PTSD—the use of SSRIs and other antidepressants (see later), not a surprising finding given the symptom overlap of the two diagnoses.

Treatment of Posttraumatic Stress Disorder

Antidepressant Medications

SSRIs have been extensively studied for the treatment of PTSD, and their use is considered first-line treatment for the disorder. Two SSRIs, sertraline and paroxetine, have U.S. Food and Drug Administration (FDA) approval for the treatment of PTSD. Clinical guidelines cite four reasons for the primary use of SSRIs to treat PTSD: (1) They ameliorate all three PTSD symptoms clusters (reexperiencing, avoidance/numbing, and hyperarousal); (2) they are effective treatments for psychiatric disorders that are frequently comorbid with PTSD including depression and other anxiety disorders; (3) they may reduce problematic clinical symptoms such as suicidal, impulsive, or aggressive behaviors; and (4) they are relatively well tolerated with few side effects. Multiple studies demonstrated the superiority of SSRIs over placebos in the treatment of noncombat PTSD. SSRIs have also been shown to prevent relapse of PTSD symptoms. In one study, patients who had previously achieved remission of symptoms on fluoxetine were randomized to continue fluoxetine or switch to a placebo. Relapse rates were 22% for fluoxetine compared with 50% with placebos.

...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles

Sage Recommends

We found other relevant content for you on other Sage platforms.

Loading